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Systemic juvenile idiopathic arthritis (JIA) is the most
severe category within the group of arthritis which are
classified under the umbrella term of JIA. Systemic JIA
has been considered a therapeutic orphan until few years
ago when the disease was treated primarily with corticos-
teroids with the known side effect especially on child
growth. More recently the availability of new treatment
modalities with biologic agents such as anti L6 and anti
IL1 therapies have greatly advanced the possibilities for
these children to be adequately treated.
This lecture will describe the current status of the
treatment for systemic JIA and the future perspectives.
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